Schonfeld Strategic Advisors’s AbCellera Biologics ABCL Stock Holding History

Schonfeld Strategic Advisors’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$493K	Buy	141,295 +121,715	+622%	+$438K	﹤0.01%	1394
2025 Q4	$67K	Buy	+19,580	New	+$87.4K	﹤0.01%	1862
2023 Q4	–	Sell	-358,400	Closed	-$1.65M	–	1828
2023 Q3	$1.65M	Buy	358,400 +211,000	+143%	+$1.28M	0.01%	880
2023 Q2	$952K	Buy	147,400 +65,500	+80%	+$447K	0.01%	999
2023 Q1	$618K	Sell	81,900 -72,900	-47%	-$662K	0.01%	1112
2022 Q4	$1.57M	Sell	154,800 -67,900	-30%	-$784K	0.01%	927
2022 Q3	$2.2M	Buy	222,700 +84,400	+61%	+$926K	0.02%	825
2022 Q2	$1.47M	Buy	138,300 +14,400	+12%	+$122K	0.01%	847
2022 Q1	$1.21M	Buy	+123,900	New	+$1.17M	0.01%	905
2021 Q4	–	Sell	-57,540	Closed	-$1.15M	–	2082
2021 Q3	$1.15M	Buy	+57,540	New	+$1.02M	0.01%	906

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Schonfeld Strategic Advisors's ABCL Position: Q1 2026 in Review

Schonfeld Strategic Advisors increased its AbCellera Biologics (ABCL) stake by 622% in Q1 2026, buying an estimated $438K and bringing the position to 141,295 shares worth $493K. The position accounts for ﹤0.01% of the portfolio, ranked #1394.

Schonfeld Strategic Advisors first reported a position in ABCL in Q3 2021 and has held it in 10 quarters since. The position peaked at $2.2M in Q3 2022. 138 funds tracked by Wall St. Rank hold ABCL as of Q1 2026.

Schonfeld Strategic Advisors held 141,295 shares of AbCellera Biologics worth $493K as of Q1 2026.
Schonfeld Strategic Advisors bought 121,715 AbCellera Biologics shares in Q1 2026, an estimated $438K.
AbCellera Biologics made up ﹤0.01% of Schonfeld Strategic Advisors's portfolio in Q1 2026, its #1394 holding.
Schonfeld Strategic Advisors first reported a position in AbCellera Biologics in Q3 2021 and has held it in 10 quarters since.
Schonfeld Strategic Advisors's AbCellera Biologics position peaked at $2.2M in Q3 2022.
138 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.